Home › Trials › NCT06728670
Clinical trial Recruiting at 1 site Interventional Ages 20 to 64 Women only

Study of how tranexamic acid works in ovarian cancer patients

Official title: Pharmacokinetic Study and Clinical Efficacy Observation of Different Routes of Tranexamic Acid Infusion in Advanced Ovarian Cancer Cell Reduction Surgery

Run by Zhejiang Cancer Hospital · NCT06728670 · Data updated 2026-11-12

This study is testing how well tranexamic acid works in reducing blood loss during surgery for women with advanced ovarian cancer by comparing two different ways of giving the medication.

More Epithelial Ovarian Cancer trials

Quick facts

Study typeInterventional
Ages20 Years to 64 Years
SexWomen only
Enrollment30 (estimated)
SponsorZhejiang Cancer Hospital
Academic / other
Locations1 site (Hangzhou, Zhejiang)
StatusRecruiting
StartedNovember 20, 2024
Main results expectedMarch 31, 2025
Study endsAugust 31, 2025
Registry record updatedDecember 11, 2024
Trial IDNCT06728670 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adult women aged 20-64 with advanced ovarian cancer (stage III-IV) who are scheduled for cytoreductive surgery.

Probably not a fit

Patients with renal or liver dysfunction, serious mental illness, bleeding disorders, or those allergic to TXA may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the pharmacokinetics of tranexamic acid (TXA) in adult women with advanced ovarian cancer undergoing cytoreductive surgery. It aims to compare the effects of TXA administered through intravenous and intramuscular routes on intraoperative blood loss, transfusion volume, and postoperative complications. A total of 30 patients will be recruited, and their pharmacokinetic parameters will be recorded to understand how different administration methods impact treatment outcomes.

Why it matters

Potential benefit: If successful, this study could optimize the use of tranexamic acid to reduce blood loss and improve recovery in ovarian cancer patients undergoing surgery.

How similar studies have gone: While there is limited data on the pharmacokinetics of TXA in ovarian cancer patients, previous studies have shown its effectiveness in reducing blood loss in surgical settings.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Adult women aged 20-64 diagnosed with advanced ovarian cancer undergoing cytoreductive surgery
2. The cancer stage is III-IV
3. ASA classification II-III
4. Surgical duration\>2 hours

Exclusion Criteria:

1. Renal dysfunction (serum creatinine\>200 mmol/L) or liver dysfunction (Child Turcote classification\>6)
2. Has a history of serious mental illness or disorders, epilepsy, visual impairment
3. Previous or current bleeding disorders, coagulation dysfunction, or thromboembolic events
4. Lower limb venous thrombosis
5. Anticoagulants or antifibrinolytic drugs used before surgery within the past month
6. Allergic to TXA

Where it's running

  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang, China     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Ovarian Neoplasm Epithelial 3Zhejiang Cancer Hospital 67
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.